(56 days)
The Genesys Spine 3DP Lumbar Interbody System is indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The system is designed for use with supplemental fixation and with autograft to facilitate fusion.
The Genesys Spine 3DP Lumbar Interbody System is comprised of additively manufactured lumbar intervertebral body fusion devices. Numerous styles, footprints, and sizes of interbodies are offered including PLIFs, TLIFs, ALIFs, and LLIFs. The 3DP Lumbar Interbody System implants are manufactured from titanium Ti-6AL-4V ELI alloy.
This document is a 510(k) Premarket Notification from the FDA regarding a medical device called the "Genesys Spine 3DP Lumbar Interbody System." It discusses the regulatory approval process for this device and its indications for use.
Crucially, the document states "PERFORMANCE DATA Not Required." It explains that "Engineering analyses were performed on the Subject Devices and it was determined that a new worst-case was not created, therefore additional testing was not required. The instrument additions mimic previously cleared instruments with minor alterations."
Therefore, based on the provided text, there is no study described that proves the device meets specific acceptance criteria based on performance data. The approval is based on a determination of substantial equivalence to a predicate device (Genesys Spine 3DP Lumbar Interbody System - K182987) and engineering analyses, rather than new clinical or performance testing.
Given this, I cannot provide the requested information as it does not exist within the provided document. The sections you asked for, such as acceptance criteria, specific performance data, sample sizes, expert involvement, and ground truth establishment, are not detailed because new performance data was not required for this specific 510(k) submission.
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.